SinoMab BioScience Limited announced the grant of 11.57 million share options on 24 March 2026 under its 2022 Share Option Scheme, which was adopted on 26 October 2022 and amended on 14 June 2024. The options were awarded to two employees, one of whom is a member of senior management.

The exercise price is set at HK$1.94 per share, matching the closing price on the grant date and exceeding the five-day average closing price of HK$1.736. Each option entitles the holder to subscribe for one new share.

Exercisable periods and vesting: • Senior management: options are exercisable from 25 March 2027 to 24 March 2036, vesting in four equal tranches of 25 % annually from 25 March 2027 to 25 March 2030. • Other employee: options are exercisable from 25 March 2028 to 24 March 2036, vesting in four equal tranches of 25 % annually from 25 March 2028 to 25 March 2031.

The grant size was determined by position, tenure and performance evaluations. No clawback clause or company-provided financial assistance applies. After this grant, 40.95 million shares remain available for future issuance under the scheme mandate, while the service-provider sub-limit is fully utilised.